Laboratory of Tissue Pharmacology, Department of Internal Medicine and Clinical Pharmacology, Medical University of Lodz, Poland.
Arch Med Sci. 2013 Feb 21;9(1):159-65. doi: 10.5114/aoms.2013.33355.
For many years atherosclerosis was believed to be the passive accumulation of cholesterol in vessel walls. Today the picture is more complex, as immune processes occur in atherogenesis. Considerable attention is focused on the particular role of adaptive immune responses orchestrated by T cell subsets. Since the role of Th1/Th2 balance and Th1 cell domination in atherogenesis is already known, the involvement of regulatory T lymphocytes and recently described Th17 cells raises new concerns. On one hand, each of these cells may specifically drive responses of vascular wall tissues and immune cells; however, they are subject to the control of a plethora of tissue- and pathogen-derived agents. Due to ineffective tissue regeneration, remodeling of the vascular wall occurs. The understanding of the immune regulatory network gives perspectives of innovative immunomodulatory therapies of atherosclerosis and the prevention of its complications, such as coronary artery disease.
多年来,人们一直认为动脉粥样硬化是胆固醇在血管壁中的被动积累。如今,这种情况更加复杂,因为免疫过程发生在动脉粥样硬化形成中。人们非常关注 T 细胞亚群协调的适应性免疫反应的特殊作用。由于 Th1/Th2 平衡和 Th1 细胞在动脉粥样硬化形成中的主导作用已经为人所知,调节性 T 淋巴细胞和最近描述的 Th17 细胞的参与引起了新的关注。一方面,这些细胞中的每一个都可能专门驱动血管壁组织和免疫细胞的反应;然而,它们受到大量组织和病原体衍生的物质的控制。由于组织再生无效,血管壁发生重塑。对免疫调节网络的理解为动脉粥样硬化的创新性免疫调节治疗及其并发症(如冠心病)的预防提供了新的视角。